Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Webcast | Smarter science, sharper strategy: Expert perspectives from ASCO® 2026

June 18, 2026 | ASCO, Congress, Pharma, healthcare, oncology, webinar 

Key insights from ASCO® 2026, including oncology trends, scientific highlights, and strategies for smarter congress engagement.

- PMLiVE

Join our team for an expert debrief from ASCO® 2026. With a front-row seat across multiple client engagements, we’ll share the scientific highlights, attendee perspectives and strategic lessons from one of oncology’s most important annual gatherings, while exploring what smarter, more measurable congress engagement looks like in practice.

What we’ll cover

  • Key scientific and strategic themes emerging from ASCO® 2026
  • Attendee perspectives and trends shaping oncology congress engagement
  • Lessons from real-world client engagements and launch environments
  • Smarter approaches to congress strategy, engagement and measurement
  • Opportunities to drive sharper strategic decision-making through congress insights

The experts shaping the conversation

  • Mark Jackson, Managing Director, Emota, an Inizio Engage company
  • Matt Hoelzle, Chief Medical Officer, Inizio Evoke
  • Simon Davenport, Global Head of Exhibitions and Environments, Emota, an Inizio Engage company
  • Nick Bellomo, Director of Technology and Engagement, Inizio Medical
  • Jo Ann Saitta, Global Head of Data Strategy, Analytics, and AI, Inizio Ignite
  • Lynsey Holbrook, Global Client Development Director, Emota, an Inizio Engage company
Watch the webcast here.

This content was provided by Inizio

Company Details

- PMLiVE

Inizio

Email
Website

 Latest Content from  Inizio 

How we applied user-led design thinking in the ER setting to improve patient care

The challengeOur client needed to identify the key delivery-device attributes for an antibiotic topical treatment used to combat a group of infections typically affecting young children. Current treatment is a…

Research conducted by Research Partnership published in leading medical journal

Findings from a study conducted by Research Partnership have recently been published in the ‘Supportive Care in Cancer’ journal

Products come and go, but a pharma company’s most valuable, durable asset is its reputation, writes Duncan Mackenzie-Reid and Simon Grist

Hiding between the lines of any company’s ledgers is an intangible asset, invisible to most auditors, but with the potential to have a very real impact on bottom line. Pharma…

Webcast: Rich in potential – Exploring the opportunity for nutritionals in emerging markets

Watch the webcast: http://bit.ly/2oTpzFjA shift to preventative health has seen nutritionals emerge as a rapidly developing area in recent years. But while growth begins to level off in more established territories,…

A researcher’s guide to Key Driver Analysis

Research Manager Kayleigh Simpson explores how Key Driver Analysis can be used to answer key business

Research Partnership sends a cheque for $10,000 to Forever Angels

Helping them in their mission of caring for and improving the lives of orphans and abandoned infants in Tanzania

Pharma Market Research Conference, 2018

We are delighted to be presenting and exhibiting at PMRC, 14-15 February in Newark, NJ.

Out of the shadows: Mental health in the Asia Pacific region

In the first of a series of articles exploring mental health in emerging markets we take an in-depth look at the situation in Asia

Research Partnership has published a new patient Living with Atopic Dermatitis (US) report

Living with Atopic Dermatitis (AD) is a report based on a new study conducted amongst adult sufferers and parents of child sufferers. The report consists of 45-minute quantitative and 30-minute qualitative…

Research Partnership has published a new patient Living with Psoriasis (EU) report

Living with Psoriasis is a report based on a new study conducted in the main 5EU markets and Belgium and the Netherlands (reports can be purchased for either 5EU or 7EU)….